A new multicenter study shows that the survival benefit of complete diagnostic evaluation may not outweigh the associated potential costs, pain and anxiety in older patients with myelodysplastic syndromes.
Researchers have developed the first machine-learning model that can predict with high accuracy MDS patient response or resistance to HMA treatment.
A clinical trial testing a new combination therapy for higher-risk leukemias finds no increase in adverse events and an association with better survival rates, Cleveland Clinic researchers report.
The investigational agent lustpatercept significantly lessens anemia severity and reduces or eliminates the need for transfusions in patients with low-risk myelodysplastic syndromes, a new phase 3 study involving Cleveland Clinic Cancer Center has found.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy
Early data from The National MDS Study highlight the need for referral to a center with deep expertise in blood disorders.
Jaroslaw Maciejewski, MD, PhD, discusses the prognostic relevance of CHIP mutations, the need for closer monitoring of patients who harbor them and current plans to establish Cleveland Clinic’s first CHIP clinic.
A new whole-exome sequencing study uncovers the dynamics of genetic alterations during progression of MDS to more aggressive acute leukemia and clarifies the impact of specific genetic defects on expected clinical behavior.
A 22-year-old is cured of aplastic anemia and PNH thanks to a half-match bone marrow transplant. Cyclophosphamide after transplant helped counter graft rejection and graft-versus-host disease.
Radiation treatment for prostate cancer inadvertently irradiates the surrounding pelvic bones, which hold more than half the body’s active bone marrow mass. But a Cleveland Clinic study finds that men who undergo the procedure have no greater risk of developing myelodysplastic syndromes than the general population.
Healthcare providers and patients have disparate views of the course of MDS and the value and limitations of treatment. Improved communication and education may increase understanding of the diseases and improve outcomes.